⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication.
Polycystic ovary syndrome (PCOS) — called PCOD (polycystic ovarian disease) in much of India, though the two terms refer to the same condition — is the most common hormonal disorder in Indian women of reproductive age. An ICMR study estimates that 9–18% of Indian women have PCOS, with some urban surveys suggesting prevalence as high as 22%. That means roughly 1 in 5 Indian women you know may be managing irregular periods, elevated androgens, insulin resistance, and often significant weight challenges.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) — have emerged as one of the most promising treatments for the metabolic component of PCOS in recent years. Multiple clinical trials and real-world studies published between 2021 and 2024 show improvements not just in weight, but in insulin resistance, androgen levels, menstrual regularity, and quality of life in women with PCOS who are treated with GLP-1 medications.
This guide explains what PCOS is, why GLP-1 medications are particularly well-suited for managing it, what the clinical evidence shows, and what Indian women considering or already using these medications need to know.
PCOS is fundamentally a metabolic and hormonal condition, not just a gynaecological one. Its core features are:
The underlying driver in the majority of cases, particularly in Indian women, is insulin resistance — the same metabolic dysfunction at the heart of type 2 diabetes and obesity. When cells resist insulin's signal, the pancreas produces more insulin. Elevated insulin stimulates the ovaries to produce excess testosterone, disrupting the ovulatory cycle and producing the characteristic features of PCOS.
Indian women with PCOS face an additional challenge: lean PCOS. Unlike Western populations where PCOS is strongly associated with obesity, a meaningful proportion of Indian women develop severe PCOS symptoms at normal BMI due to the higher rates of insulin resistance in South Asian bodies even at lower weights.
GLP-1 agonists address PCOS through multiple mechanisms simultaneously:
1. Reducing insulin resistance GLP-1 medications stimulate glucose-dependent insulin secretion and improve cellular insulin sensitivity. This directly targets the root metabolic cause of PCOS, lowering the insulin excess that drives androgen overproduction.
2. Promoting weight loss For overweight women with PCOS, even a 5–10% reduction in body weight significantly improves hormonal parameters, menstrual regularity, and ovulatory function. GLP-1 medications produce the most consistent, sustained weight loss of any currently available non-surgical intervention.
3. Lowering testosterone and androgens Multiple studies show that GLP-1 agonists reduce free testosterone and total androgen levels in women with PCOS, leading to reduced acne, slowed hirsutism progression, and in some patients, improvement in scalp hair loss.
4. Improving menstrual regularity A 2023 study published in Fertility and Sterility found that semaglutide treatment over 6 months restored regular menstrual cycles in 74% of women with PCOS who had previously had irregular periods, compared with 22% in the lifestyle intervention control group.
5. Reducing ovarian cyst burden Several case series and smaller RCTs report reduction in antral follicle counts and ovarian volume following GLP-1 therapy in women with PCOS, though larger confirmatory trials are ongoing.
Comparison with metformin: Metformin has been the standard first-line medical treatment for metabolic PCOS in India for decades. Head-to-head comparisons show GLP-1 medications produce 3–4 times greater weight loss, greater improvements in insulin resistance, and comparable or better hormonal outcomes versus metformin alone. Some Indian endocrinologists are now combining both — metformin handles the foundational insulin sensitisation while GLP-1 drives weight loss and additional metabolic benefit.
As of 2026, none of the GLP-1 medications have a formal PCOS indication approved by CDSCO (India's drug regulator). Their use in PCOS is off-label, prescribed by endocrinologists and gynaecologists based on clinical evidence for their metabolic effects.
Semaglutide (Ozempic, Wegovy): Most studied; Ozempic is the most widely available and prescribed GLP-1 in India for PCOS-related metabolic management. Wegovy (2.4 mg weight-loss dose) is available in India but significantly more expensive.
Tirzepatide (Mounjaro): Increasingly used in urban India; shows particularly strong insulin-sensitising effects that may be especially beneficial in severe insulin-resistant PCOS. More expensive than semaglutide.
Rybelsus (oral semaglutide): Some patients with needle aversion prefer this option; clinical data in PCOS specifically is more limited, but the drug mechanism is identical.
PCOS is a leading cause of anovulatory infertility. Many Indian women on GLP-1 medications for PCOS management are of reproductive age and may be trying to conceive.
Key facts:
Reduced androgen levels from GLP-1 therapy typically lead to:
Stopping medication when periods return: Some women stop GLP-1 therapy once menstrual cycles normalise, assuming the problem is solved. PCOS is a chronic metabolic condition — the underlying insulin resistance and tendency to androgen excess return when the drug is stopped and weight is regained.
Using GLP-1 as the only treatment: GLP-1 medications work best as part of a comprehensive PCOS management plan that includes dietary changes (low-glycaemic Indian meals), resistance exercise, stress management, and appropriate supplementation (vitamin D, inositol, omega-3).
Ignoring thyroid co-morbidity: Hypothyroidism co-occurs with PCOS in approximately 20–30% of Indian women. Both conditions cause weight gain and menstrual irregularity. If a GLP-1 medication does not produce expected metabolic improvement, an undiagnosed thyroid disorder is often the reason. Ensure thyroid function is tested before and during GLP-1 therapy.
Expecting rapid cosmetic results: GLP-1 addresses the metabolic root of PCOS. Cosmetic improvements in acne and hair follow the hormonal normalisation — this takes months, not weeks.
Consult an endocrinologist or reproductive endocrinologist in India if you have PCOS and:
GLP-1 medications for PCOS in India are typically prescribed by endocrinologists. A good starting point is a referral from your gynaecologist to an endocrinologist who manages PCOS metabolically, rather than only gynaecologically.
Q: Is semaglutide approved for PCOS in India? No. Its use in PCOS is off-label based on evidence for its metabolic effects. It is legally prescribable in India by qualified physicians including endocrinologists, but CDSCO approval is for type 2 diabetes and obesity management only.
Q: Can I take GLP-1 with metformin for PCOS? Yes, combination therapy is common and well-tolerated. The two drugs have complementary mechanisms and additive metabolic benefits. GI side effects may be more prominent initially.
Q: Will GLP-1 cure my PCOS? PCOS has no cure, but GLP-1 medications can achieve significant metabolic remission of the insulin-resistant component. Many women experience normalised periods, reduced androgens, and improved fertility markers during treatment. These benefits typically require ongoing treatment to maintain.
Q: I have lean PCOS with a normal BMI. Will GLP-1 help me? Potentially yes, particularly if you have documented insulin resistance or elevated fasting insulin on blood tests. However, the evidence base is less established for normal-weight PCOS than for overweight PCOS. Discuss the risk-benefit balance carefully with your doctor.
